I've passively followed this field as a layman observer for the past several years. I'd be interested in getting a lot more information on this work. Generall

I've passively followed this field as a layman observer for the past several years. I'd be interested in getting a lot more information on this work. Generally I view these press releases with a skeptical eye, as the researchers have a need to "talk up" their work in order to keep the funding coming in. On the other hand, Irving Weissman and the labs at Stanford are well respected and not known for spurious claims - often though, the problem with these therapies isn't so much potency as it is persistence, with recurrences being relatively common longer term (and many therapies simply don't translate from mice to humans well). I'd be interested in having someone with in-depth knowledge of this field explain how the OX40 receptor work here differs from the CD47 work also being carried out at Stanford (besides being a different target protein), and existing CAR T therapies being tested elsewhere - although certainly this seems very encouraging in any case.